Loading, Please Wait...
SALT LAKE CITY, July 31, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq: COOL) today announced the appointment of Alain Adam as Vice President of Sales. Mr. Adam will lead the company’s continued development of its commercial strategy, sales force buildout, and execution.
Mr. Adam has nearly 18 years of life-sciences experience including sales and sales leadership, national accounts, market development and commercial enablement. Most recently, he was Managing Director, Breast Oncology and Global Director Commercial Acceleration for Medtronic. Before that, he worked in various commercial leadership roles for large and start-up organizations including, Sonitus Medical, Acclarent (acquired by Johnson & Johnson), and Covidien (acquired by Medtronic). Mr. Adam holds a B.A. from University of Illinois-Champaign, Urbana.
“We are excited to name Alain to this new role just as we move from the limited market release of SkinTE to national commercialization. During the first phase of market introduction, we received positive feedback on the clinical outcomes of SkinTE from patients and providers. Now that we have progressed into full commercialization, Alain’s experience and knowledge will be critical in building a national salesforce. This will help drive product revenues that will allow us to achieve our commercial milestones,” said Denver M. Lough, MD, PhD, Chairman and Chief Executive Officer of PolarityTE.
Alain said, “I am very pleased to join the PolarityTE team to enable access to a platform solution that will potentially empower providers to elevate the standard of care for patients, with the potential to alleviate the economic burden on our healthcare system. I am excited to begin working with clinicians and administrators that seek to deliver holistically transformative solutions to stakeholders in their respective communities.”
PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The PolarityTE platform technology begins with a small piece of the patient’s own, or autologous, healthy tissue, rather than artificially manipulated individual cells. From this small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to enhance and stimulate the patient’s own cells to regenerate the target tissues. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient’s own tissue and uses the patient’s own body to support the regenerative process to create the same tissue from which it was derived. PolarityTE’s innovative method is intended to promote and accelerate growth of the patient’s tissues to undergo a form of effective regenerative healing.
SkinTE is intended to be used by physicians or other appropriate healthcare providers for homologous uses of skin tissues/integument. Patients who have suffered from an event, disease, process or acquired deficit that results in the functional loss or void of skin/integument systems can receive SkinTE as an adjunct and/or in place of split-thickness skin grafting, full-thickness grafting, temporizing skin coverage and/or skin substitute products.
SkinTE is for autologous use only. Aseptic technique during harvest and deployment of SkinTE is mandatory.
SkinTE is regulated by the FDA as an HCT/P solely under Section 361 of the Public Health Service Act and 21 CFR 1271. The FDA has specific regulations governing HCT/Ps. HCT/Ps that meet the criteria for regulation solely under Section 361 of the Public Health Service Act and 21 CFR 1271 (361 HCT/Ps) are not subject to pre-market clearance or approval requirements, but are subject to post-market regulatory requirements.
Forward Looking Statements
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as “believes,” “may,” “expects,” “anticipates,” “intend,” “plan,” “will,” “would,” “should” and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company’s beliefs and assumptions as of the date of this release. The Company’s actual results could differ materially due to risk factors and other items described in more detail in the “Risk Factors” section of the Company’s Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. Our actual results could differ materially due to risk factors and other items described in more detail in the “Risk Factors” section of the Company’s Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov).
POLARITYTE, the POLARITYTE logo, and SKINTE are trademarks or registered trademarks of PolarityTE, Inc.
LifeSci Advisors, LLC
Russo Partners LLC